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• Opioids remain the mainstay for acute perioperative pain management, but could be clinically less effective due to development of either tolerance or opioid-induced hyperalgesia.
• Both tolerance and hyperalgesia can occur simultaneously and it can be difficult to differentiate between them.
• Although different opioids vary in their effects on the immune system, any clinical relevance is still to be determined.
• A number of 'adjuvant', opioid-sparing analgesic strategies may be used to diminish the dose-related adverse effects of opioids.
Opioids remain the mainstay of perioperative pain management for many surgical procedures and settings. However, they are well known to cause side-effects, including nausea, vomiting, hallucinations, urinary retention, constipation, somnolence, and respiratory depression. More recently, there have been some concerns regarding their long-term antinociceptive effects due to the development of tolerance or hyperalgesia. 1 There have also been reports of suppression of the immune system by opioids. 1 In this review, the evidence and the possible mechanisms for the occurrence of acute tolerance, hyperalgesia, and immunosuppression in the perioperative setting will be explored. Evidence-based opioid-sparing treatments may be used in the perioperative setting to diminish the dose-related adverse effects of opioids.
Antinociceptive effects of opioids

Opioid tolerance and hyperalgesia
Tolerance occurs when a patient's response to a drug reduces over time and necessitates an increase in dose to maintain the desired result. This results from desensitization of opioid receptors due to a number of mechanisms as outlined below. Opioid-induced hyperalgesia (OIH) is a state of pain receptor sensitization caused by exposure to opioids. Clinically, this is recognized by a paradoxical response to opioid analgesics. While opioids are being used to manage the pain, they may actually result in an increase in sensitivity to painful stimuli. Therefore, any further increase in the opioid dose could result in an increased perception of painful stimuli. 2 There is strong positive evidence from animal studies, which suggest that opioid tolerance and OIH do exist in an acute perioperative setting. But the evidence from clinical studies is at best equivocal, questioning if the dose and duration of opioid use is significant enough to cause acute tolerance or OIH. A recent systematic review and meta-analysis demonstrated that high intraoperative doses of opioids were associated with significantly higher postoperative pain intensity, and morphine consumption, supporting the existence of OIH in the postoperative setting. The prevalence of tolerance and OIH in acute pain remains unknown. Diagnosis of tolerance, OIH, or both is difficult and to complicate matters, can co-exist. Distinguishing OIH from tolerance may be achieved by increasing the opioid dose and observing the effect on the patient's pain levels. Increased pain implies OIH, whereas reduction suggests tolerance (Fig. 1) .
2 OIH can also be characterized using tools such as quantitative sensory testing (QST). 2 QST changes suggesting increased sensitivity to stimuli have been demonstrated both locally at the site of pain and at remote non-painful sites, such as a contralateral limb. Opioid use has been associated with decreased heat pain threshold and tolerance, exaggerated response to temporal summation, and abnormal conditioned pain modulation (diffuse noxious inhibitory control) paradigms. 4 This may help to differentiate tolerance from hyperalgesia. Current literature suggests that higher early postoperative pain scores and associated greater opioid dose could be attributed to OIH, whereas greater requirement for opioids later during recovery may be attributed to tolerance.
Mechanisms of tolerance 5
• Up-regulation of the cAMP pathway resulting in phosphorylation of the μ-receptor by a variety of intracellular second messengers, including G-protein-coupled receptor kinase, mitogen-activated protein kinase, protein kinase C, and phospholipase C.
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• Functional decoupling of receptors from G-proteins or μ-opioid receptor internalization, receptor down-regulation, or both.
• N-methyl--aspartate receptor (NMDAR), nitric oxide system-acute opioid administration has been shown to increase NMDAR activity in mouse models resulting in tolerance, and NMDA antagonists have been shown to suppress the development of acute tolerance.
• On exposure to opioids, glial cells expressing opioid receptors release pro-inflammatory neurotransmitters such as NO and protein kinase C. Opioids also activate glial cells via Toll-like receptor-4 (TLR-4). The inhibition of TLR-4 has been shown to reduce tolerance and thereby improve opioid analgesia.
Mechanisms of OIH
The mechanisms of OIH are well illustrated in a previous CEACCP article. 2 In summary, the proposed mechanisms include NMDAR Increased nociceptive activity leads to increased NMDAR activation by the neurotransmitter, glutamate. Opioid-induced NMDAR activation results in further glutamate release. In the dorsal horn, μ-opioid receptors co-localize at the same neurones as those that use glutamate to transmit pain signals. Although the influence of these receptors is usually to dampen pain sensation, a still poorly understood mechanism appears to exist, in which activation of these receptors leads to a calcium influx, rendering the neurones more excitable, predisposing to hyperalgesia. In addition, the calcium influx activates nitric oxide synthase (NOS) which produces nitric oxide, a pain-signalling neurotransmitter. 2 6 Remifentanil: antinociceptive effect Remifentanil is a highly potent, ultra-short-acting opioid analgesic used for intraoperative sedation and analgesia. Both tolerance and hyperalgesia have been implicated even with short-term infusion of remifentanil. This is supported by studies on animal models, human volunteer, and clinical studies. 3 A recent systematic review
showed an association between intraoperative remifentanil use and increased postoperative pain intensity at rest, and also higher morphine consumption (by as much as 18 mg morphine equivalent dosage) in the first 24 h after surgery. Remifentanil was also associated with measurable hyperalgesia as assessed by a decreased nociceptive threshold.
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A study based on a large cohort of Chinese patients showed that age <16 yr, duration of surgery (>2 h), and dose of remifentanil (>30 µg kg −1 ) are risk factors for developing remifentanil-induced hyperalgesia (RIH). High-dose remifentanil infusions, over a prolonged duration followed by rapid withdrawal, may result in the development of hyperalgesia and possibly tolerance. Genetic factors such as homozygous polymorphism for the met (158) allele of the COMT gene and chronic preoperative opioid use have also been associated with higher risk of RIH. 7 RIH has also been cited as a possible factor in the development of chronic pain. 8 
Opioid-induced immunosuppression
Perioperative immunosuppression should be minimized in order to facilitate recovery from the surgery without complications such as wound infection. It has also been surmised that impaired immune function may play a role in the spread of cancer, although this is not clinically proven and remains highly controversial. A number of perioperative factors have been shown to have a bearing on the immune status including surgery and tissue handling, anaesthetics, pain, and analgesics. Research interest has focused on possible differences in the effects on immune function of different opioids, local anaesthetics, and regional anaesthetic techniques, and on rates of cancer recurrence. Studies have suggested that pain itself is associated with impaired immune function by affecting the hypothalamo-pituitaryadrenal (HPA) system, and by suppressing natural killer (NK) cells. 1 In the acute postoperative period, analgesics can potentially offset the deleterious effects of pain on the immune system by reducing nociception and the stress response. However, both animal and human studies show that opioids themselves may have deleterious effects on immune function. 9 Several mechanisms have been proposed, although the exact mechanism of opioid-induced immunosuppression (OII) is still not clear. Opioids impair the phagocytic and chemotactic function of neutrophils, monocytes, and macrophages and the response of B and T lymphocytes and also promote their apoptosis. They also suppress NK cell, antibody function, and lymphocyte proliferation in response to mitogens. 9 Central actions on corticosteroid production and norepinephrine levels, involving the HPA axis and the sympathetic nervous system, have been described, and also peripheral mechanisms involving opioid and non-opioid receptors, although whether lymphocytes express opioid receptors remains highly controversial. 1 9 A study on a mouse model showed that administration of morphine suppressed the NK cell activity and the splenic T-cell proliferation in a normal animal but not in a µ-opioid receptor-deficient animal, suggesting the role of the µ-opioid receptor in mediating the immunosuppressive effect of opioids. 10 In contrast, perioperative and especially preoperative administration of morphine resulted in attenuation of surgery-induced tumour retention in rats undergoing laparotomy. 9 In another study, when morphine was used to treat cancer pain in rat models inoculated with melanoma cells, it resulted in the suppression of the tumour growth and metastasis. 9 After careful consideration of the conflicting evidence on OII, and cancer spread, the British Journal of Anaesthesia published a consensus statement recently on cancer and anaesthesia, which states that there is currently insufficient evidence to associate opioid use with cancer promotion or spread. 
Opioid-sparing strategies
The majority of the opioid-related side-effects are dose-related and hence the rationale for 'opioid-sparing' strategies, to decrease the opioid dose. Such dose reduction may also serve to reduce the likelihood and degree of OIH and OII. The adjuvant analgesic measures include local anaesthetic techniques and systemic pharmacological analgesia as summarized in Table 1 and is explained in greater detail below.
Local anaesthetic techniques
Regional anaesthesia decreases opioid requirement and may suppress the stress response to surgery. The benefits of regional techniques such as central neuraxial blocks (spinal, epidural, and paravertebral blocks) and peripheral local anaesthetic techniques (nerve blocks and wound infiltration/catheter) are well established in both animal and human studies. 9 They not only provide good analgesia but also have extra-analgesic benefits including improved respiratory and gut function. In addition, a Cochrane systematic review and meta-analysis suggest that regional anaesthesia techniques such as epidural or paravertebral analgesia for thoracotomy and breast surgery may result in a decreased incidence of chronic pain.
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Both lidocaine and ropivacaine have also been shown to have anti-tumour effects. They inhibit epidermal growth factor receptor (EGFR), voltage-gated sodium channels (VGSC), kinesin motor machinery, and inflammatory Src signalling in vitro. 9 13 Local anaesthetics are also cytotoxic to mesenchymal stem cells and impair human fibroblast growth. They result in the suppression of tumour cell proliferation, differentiation, and metastasis. Lidocaine infiltration has been shown to protect against tumour cell invasion at concentrations used routinely in surgical practice. 13 So, the use of regional anaesthesia using local anaesthetics may decrease the degree of immunosuppression by a combination of direct drug effect and by sparing the use of opioids. A retrospective study on the use of epidural analgesia for open prostate surgery showed a 57% reduction in biochemical cancer recurrence. 9 Another retrospective study showed that general anaesthesia along with paraverebral block for mastectomy and axillary clearance for breast cancer was associated with significantly decreased cancer recurrence and greater metastasis-free survival compared with general anaesthesia and standard PCA morphine {94% [95% confidence interval (CI), 87-100%] vs 82% (74-91%) at 24 months (P=0.038) and 94% (87-100%) vs 77% (68-87%) at 36 months (P=0.007); P=0.012}. Contrary to these small retrospective positive studies, the Cochrane review, which included four studies involving 746 patients, concluded that currently there is insufficient evidence to support the benefit of regional anaesthesia techniques on tumour recurrence. 14 However, the authors of the Cochrane review commented that overall, the studies comprised low to very low quality evidence for the outcome measures. A longer-term evaluation (ranging from 9 to 15 yr) has been based on a follow-up of patients from the MASTER trial, who had undergone major abdominal surgery for cancer. Epidural analgesia was not associated with an improved cancer-free survival [2.8 (95% CI 0.7-8.7) yr in the control group vs 2.6 (0.7-8.7) yr in the epidural group (P=0.61)]. 15 Currently, there is an ongoing large multicentre trial looking at the role of i.v. lidocaine in improving perioperative analgesia and cancer recurrence (http://clinicaltrials.gov/show/NCT01204242).
Systemic pharmacological interventions
As described in a previous CEACCP article, several 'adjuvant' drugs have been used as part of balanced multimodal analgesia to improve perioperative analgesia, minimize opioid-related side-effects, or both. 16 
Ketamine
Ketamine is a non-competitive inhibitor of NMDAR. It prevents central sensitization and decreases mechanical hyperalgesia surrounding the surgical incision. Perioperative ketamine infusion has been found to significantly decrease the hyperalgesia and allodynia in patients receiving high-dose remifentanil infusion. 6 Ketamine has been successfully used for rescue analgesia in opioid-resistant pain and also for RIH. 6 16 α-2 receptor agonists
Clonidine has been shown to reverse remifentanil's lowering of pain thresholds, suggesting a potential role for α-2 receptor agonists in the modulation of OIH. 6 
Propofol
Fletcher and Martinez, 3 in the subgroup analysis of their systematic review, found that propofol had a strong preventive effect in the development of hyperalgesia after high-dose remifentanil infusion. Although the exact mechanism of this effect is not known, this is most likely mediated via the GABA receptors at the supraspinal level. 
Gabapentinoids
Gabapentinoids such as gabapentin and pregabalin act on the α2δ1 subunit of pre-synaptic calcium channels and thereby decrease the calcium ion current. They have significant opioidsparing effect and also decrease the incidence of opioid-related side-effects. Gabapentinoids may prevent central sensitization and subsequent hyperalgesia and allodynia. 16 Thus, they may be useful to prevent and treat OIH, although to date this has not been investigated.
COX-2 inhibitors
Prostaglandins (PG) are implicated in pro-nociceptive processing and stimulate the release of excitatory amino acids, such as glutamate, in the dorsal horn. Studies on both animal and human pain models have supported the role of COX-2 inhibitors in attenuating opioid tolerance and hyperalgesia. 6 9 Some tumour cells secrete PG, which oppose host cell immunity. Animal models show that COX-2 inhibitors, by inhibiting this PG secretion, have anti-tumour and anti-angiogenesis properties. 7 Long-term COX-2 inhibitor use has also been associated with lower incidence of breast cancer in women.
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Inter-opioid variability
Not all opioids have the same propensity to cause hyperalgesia and immunosuppression. Sacerdote and colleagues 17 showed that modifications at C6, the C7-8 bond, C14, and the piperidine ring result in variation in the antinociceptive and immunosuppressive properties of opioids.
Differential effect of opioids on hyperalgesia
In both the chronic non-cancer and cancer pain settings, opioid switching or rotation is one of the strategies used to manage either opioid tolerance or OIH. 5 This strategy could also be tried as a first step in an acute setting in patients either developing opioidrelated side-effects or in whom there appears to be diminishing response to a particular opioid. For example, morphine may be substituted with fentanyl. With regard to alternative opioids, methadone and buprenorphine stand out due to their unique mechanisms of action. Methadone is a weak NMDAR antagonist. Studies have shown that methadone may be effective in reducing the OIH due to prolonged high doses of other opioids. 5 But its long duration of action and possibility of cumulative toxicity means that it is less practical to use methadone for perioperative analgesia. Buprenorphine is a partial µ-receptor agonist and κ-receptor antagonist. Spinal dynorphin (κ-receptor agonist) concentration has been found to increase with opioid administration, which is one of the postulated mechanisms of OIH. Buprenorphine, by blocking the κ-receptor, can potentially offset this effect, and has been shown to have an antihyperalgesic effect in human volunteers. Tapentadol is a newer opioid, which has both agonist actions on μ-receptors and inhibition of norepinephrine reuptake. Both animal and human studies suggest that tapentadol has a superior effect on mechanical and thermal hyperalgesia and also on conditional pain modulation. 18 19 However, there are currently no studies evaluating OIH with tapentadol. The development of RIH is dose-related, and hence there is a potential benefit of limiting the dose infused. Several adjuvants have been studied to counteract the RIH. A large number of adjuvants have been shown to prevent the development of RIH, including ketamine, propofol, nitrous oxide, paracoxib, magnesium, propranolol, and pre-induction paracetamol. 3 6 Although the strength of this evidence remains weak and controversial, it is worth considering these adjuvants, for example, if a high dose of intraoperative remifentanil is anticipated or required.
Differential effect of opioids on immunosuppression
Not all opioids induce the same immunosuppressive effects. In a surgical model, NK-lymphocyte activity was maintained at preoperative levels after buprenorphine administration, while in morphine-treated rats, NK-lymphocyte activity was suppressed partially by morphine and maximally by fentanyl. Differential effects have also been demonstrated in chronic opioid administration: fentanyl (but not buprenorphine) significantly affected immune parameters such as lymphoproliferation, NK-lymphocyte activity, cytokine production, and lymphocyte number. 20 Studies have shown that both morphine and fentanyl are associated with suppression of cellular immunity and NK cell activity. 9 Buprenorphine, oxycodone, and hydromorphone are known to lack an immunosuppressive effect, whereas tramadol has been found to have an immunoprotective effect. 1 9 Tramadol has been shown to increase NK cell activity as opposed to morphine in both animal and human studies and hence found to have a potential immunoprotective effect. 7 Despite these effects, clinical relevance of the effect of different opioids is largely unknown and hence there is not a compelling need to change practice. There is a need for studies to establish whether OII is clinically relevant, and whether it should inform the choice of opioids for immunocompromised or cancer patients.
Conclusion
We need to be aware of some lesser-known and rarer side-effects of opioids, such as acute tolerance, OIH, and immunosuppression. There are several strategies that may be used as part of multimodal analgesia, including regional anaesthesia and adjuvant pharmacological interventions, to mitigate these adverse effects. Currently, the evidence to support such strategies including the choice of opioids is at best low. But this area has attracted a lot of research interest and hence it is hoped that in future we will have more concrete evidence.
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